TD Cowen Issues Pessimistic Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS) had its price target lowered by stock analysts at TD Cowen from $403.00 to $380.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s price objective suggests a potential upside of 26.79% from the stock’s current price.

A number of other analysts have also weighed in on KRYS. Jefferies Financial Group restated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Citigroup reiterated a “buy” rating on shares of Krystal Biotech in a research report on Thursday, October 15th. Royal Bank Of Canada decreased their price objective on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group initiated coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They issued a “buy” rating and a $441.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $372.40.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded up $3.81 during midday trading on Tuesday, hitting $299.71. 97,516 shares of the company were exchanged, compared to its average volume of 327,465. The firm has a 50 day simple moving average of $336.45 and a 200-day simple moving average of $308.70. The firm has a market cap of $8.87 billion, a P/E ratio of 37.38 and a beta of 0.50. Krystal Biotech has a 52 week low of $192.52 and a 52 week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The firm had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Equities research analysts expect that Krystal Biotech will post 7.33 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently modified their holdings of KRYS. BlackRock Inc. bought a new position in Krystal Biotech in the second quarter valued at approximately $1,554,113,000. William Blair Investment Management LLC acquired a new stake in Krystal Biotech during the 2nd quarter worth $211,909,000. First Trust Advisors LP grew its holdings in Krystal Biotech by 42.9% during the 1st quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after acquiring an additional 105,245 shares during the period. Janus Henderson Group PLC raised its position in shares of Krystal Biotech by 21.5% during the 1st quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock valued at $68,879,000 after acquiring an additional 47,219 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Krystal Biotech by 36.6% during the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock valued at $67,330,000 after acquiring an additional 69,840 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter EPS of $2.05, exceeding consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also topped expectations. The results were supported by continued demand for Vyjuvek. Earnings Beat May Change The Case For Krystal Biotech Stock
• Positive Sentiment: Management authorized a $400 million share-repurchase program over two years. Buybacks could support earnings per share and provide near-term demand for the stock. Krystal Biotech’s $400 Million Buyback
• Positive Sentiment: Analysts and market commentary highlighted Vyjuvek’s commercial strength, revenue growth and the possibility that the earnings beat could improve the investment outlook. Krystal Biotech Beats on Vyjuvek Strength
• Neutral Sentiment: Krystal revised its 2026 non-GAAP operating-expense outlook to $155 million–$165 million, reflecting continued investment in its clinical portfolio. Krystal Outlines $400 Million Share Repurchase
• Negative Sentiment: Third-quarter profit declined from the prior year despite the earnings beat, raising concerns about growth quality and the sustainability of profitability. Krystal’s Q3 Profit Declines
• Negative Sentiment: Timelines for parts of Krystal’s development pipeline slipped into 2027, delaying potential catalysts and contributing to investor disappointment. The buyback also creates an opportunity-cost and funding-risk debate while the company continues investing in clinical programs. Krystal Biotech Stock Stays Above Fair Value After Buyback Plan
• Negative Sentiment: With KRYS trading above some estimates of fair value and below its recent highs, investors appear to be demanding stronger forward growth to justify the valuation. Is Krystal Biotech Undervalued?

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.